Abstract

FORMULATION OF LANSOPRAZOLE FOAM TABLETS: A NOVEL APPROACH TO ENHANCED GASTROINTESTINAL THERAPY

Parthiban S., Anupama H. B.*, Chiranth Gowda B.C., Yashaswini N. R.

ABSTRACT

This study aimed to formulate controlled-release foam tablets of Lansoprazole using hydrophobic polymeric matrices comprising Ethyl Cellulose (EC), Eudragit S, and Polyvinyl Pyrrolidone (PVP). Preformulation studies confirmed drug identity and purity through melting point analysis (192–195.1°C) and UV spectroscopy (λmax at 281 nm). FTIR analysis showed no significant drug–excipient interactions, indicating chemical compatibility. Twelve formulations (F1–F12) were prepared and evaluated for precompression and post-compression parameters. All batches exhibited excellent flow properties, acceptable hardness (6.41–7.47 kg/cm²), low friability (<1%), and uniform drug content (88.45–92.26%) within pharmacopeial standards. In-vitro drug release studies showed sustained release over 8 hours, with cumulative release ranging from 87% to 91.5%. Formulations with lower EC andhigher PVP concentrations demonstrated faster release, while increased Eudragit S content contributed to improved early-phase control. Drug release followed Zero-order kinetics and fit well with the Korsmeyer–Peppas model (n > 1), indicating a Super Case II transport mechanism involving diffusion, swelling, and erosion. Among all, formulation F3 showed the most favourable release profile. The study concludes that appropriate polymer ratios can effectively modulate Lansoprazole release, supporting the development of a stable, gastro-resistant controlled- release dosage form.

Keywords: Lansoprazole, Controlled release, Foam tablets, Super Case II transport, Zero-order kinetics.